[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1746057600, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.82, "open": 1.85, "dayLow": 1.84, "dayHigh": 1.94, "regularMarketPreviousClose": 1.82, "regularMarketOpen": 1.85, "regularMarketDayLow": 1.84, "regularMarketDayHigh": 1.94, "payoutRatio": 0.0, "beta": 1.187, "forwardPE": -3.7058823, "volume": 728628, "regularMarketVolume": 728628, "averageVolume": 1491341, "averageVolume10days": 718010, "averageDailyVolume10Day": 718010, "bid": 1.86, "ask": 1.9, "bidSize": 2, "askSize": 13, "marketCap": 261352976, "fiftyTwoWeekLow": 0.765, "fiftyTwoWeekHigh": 4.08, "priceToSalesTrailing12Months": 307.4741, "fiftyDayAverage": 2.1815, "twoHundredDayAverage": 1.883045, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 141265920, "profitMargins": 0.0, "floatShares": 91483552, "sharesOutstanding": 138282000, "sharesShort": 8169591, "sharesShortPriorMonth": 4607296, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0591, "heldPercentInsiders": 0.18077, "heldPercentInstitutions": 0.66236, "shortRatio": 3.14, "shortPercentOfFloat": 0.0834, "impliedSharesOutstanding": 138282000, "bookValue": 0.909, "priceToBook": 2.079208, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -49375000, "trailingEps": -0.36, "forwardEps": -0.51, "enterpriseToRevenue": 166.195, "enterpriseToEbitda": -2.521, "52WeekChange": 0.11176467, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 1.89, "targetHighPrice": 32.0, "targetLowPrice": 6.0, "targetMeanPrice": 13.1, "targetMedianPrice": 10.5, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 126722000, "totalCashPerShare": 0.916, "ebitda": -56036000, "totalDebt": 6634000, "quickRatio": 14.28, "currentRatio": 14.96, "totalRevenue": 850000, "debtToEquity": 5.297, "revenuePerShare": 0.006, "returnOnAssets": -0.23809999, "returnOnEquity": -0.3607, "grossProfits": 850000, "freeCashflow": -27798624, "operatingCashflow": -44855000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -66.61765, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1746225411, "regularMarketTime": 1746216001, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.84615, "regularMarketPrice": 1.89, "cryptoTradeable": false, "postMarketChangePercent": -0.5291, "postMarketPrice": 1.88, "postMarketChange": -0.00999999, "regularMarketChange": 0.06999993, "regularMarketDayRange": "1.84 - 1.94", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1491341, "fiftyTwoWeekLowChange": 1.125, "fiftyTwoWeekLowChangePercent": 1.4705882, "fiftyTwoWeekRange": "0.765 - 4.08", "fiftyTwoWeekHighChange": -2.19, "fiftyTwoWeekHighChangePercent": -0.53676474, "fiftyTwoWeekChangePercent": 11.176467, "earningsTimestamp": 1740663000, "earningsTimestampStart": 1747053000, "earningsTimestampEnd": 1747485000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.36, "epsForward": -0.51, "epsCurrentYear": -0.46667, "priceEpsCurrentYear": -4.049971, "fiftyDayAverageChange": -0.29149997, "fiftyDayAverageChangePercent": -0.13362364, "twoHundredDayAverageChange": 0.0069550276, "twoHundredDayAverageChangePercent": 0.0036935005, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.3 - Strong Buy", "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]